Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.58 |
| ▸ | MMP13 | P45452 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | STS | P08842 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17221458 | 0.96 | GPR119 (0.54) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL13832841 | 0.93 | GPR119 (0.51) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL1502200 | 0.93 | GPR119 (0.51) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL13832628 | 0.93 | GPR119 (0.51) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL29132377 | 0.91 | GPR119 (0.59) | GPR119MMP13KMT2AMEN1 | |
| SCHEMBL3144442 | 0.90 | GPR119 (0.53) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL282240 | 0.89 | GPR119 (0.60) | GPR119MMP13KMT2AMEN1 | |
| SCHEMBL4686828 | 0.89 | KDM4E (0.58) | GPR119STSKDM4EPKM | |
| SCHEMBL22974958 | 0.89 | GPR119 (0.47) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL12604695 | 0.88 | GPR119 (0.53) | GPR119MMP13KMT2AMEN1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 606 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112707887-A | Preparation method of aryloxy quinoline compound | 南昌弘益药业有限公司 | 2021-04-27 | — | — | CN | claimed |
| US-5880121-A | SEROTONIN 5HT3 ANTAGONIST, USEFUL FOR TREATING ANXIETY, PHYCHIATRIC DISORDERS, NAUSEA, VOMITING AND DRUG DEPENDENCY | HOECHST MARION ROUSSEL INC. (US) | 1999-03-09 | — | — | US | claimed |
| US-20260138959-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC (KR) | 2026-05-21 | — | — | US | disclosed |
| WO-2026102212-A1 | MACROCYCLIC MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2026-05-15 | — | — | WO | disclosed |
| US-12559506-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| WO-2025244956-A1 | METHODS OF MANUFACTURING DANICAMTIV | MyoKardia, Inc. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2025-10-02 | — | — | US | disclosed |
| US-20250275952-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | MYOKARDIA INC (US) | 2025-09-04 | — | — | US | disclosed |
| CN-120398752-A | Synthesis method of (2S) -N-fluorenylmethoxycarbonyl-3- (1-tert-butoxycarbonyl-4-piperidinyl) propionic acid | 吉尔多肽生物制药(大连市)有限公司 | 2025-08-01 | — | — | CN | disclosed |
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2000021955-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | disclosed |
| EP-0700383-B1 | NOVEL 1-PHENYLALKANONE 5-HT 4? RECEPTOR LIGANDS | SYNTEX INC (US) | 1998-09-23 | — | — | EP | disclosed |
| US-5773465-A | Tartronic acids, their acetalic ethers and o-esters | DOMPE FARMACEUTICI S.P.A. (IT) | 1998-06-30 | — | — | US | disclosed |
| US-5763458-A | NERVOUS SYSTEM DISORDERS, ANXIETY, ANTIDEPRESSANTS AND COGNITION ACTIVATORS | SYNTEX (U.S.A.) INC. (US) | 1998-06-09 | — | — | US | disclosed |
| US-5656656-A | Tartronic acids, their acetalic ethers and O-esters | DOMPE FARMACEUTICI S.P.A. (IT) | 1997-08-12 | — | — | US | disclosed |
| EP-0667850-B1 | TARTRONIC ACIDS, THEIR ACETALIC ETHERS AND O-ESTERS | DOMPE FARMACEUTICI SPA (IT) | 1997-05-28 | — | — | EP | disclosed |
| EP-0667850-A1 | TARTRONIC ACIDS, THEIR ACETALIC ETHERS AND O-ESTERS. | DOMPE FARMACEUTICI SPA (IT) | 1995-08-23 | — | — | EP | disclosed |
| WO-1994027965-A1 | NOVEL 1-PHENYLALKANONE 5-HT4 RECEPTOR LIGANDS | SYNTEX (U.S.A.) INC. (US) | 1994-12-08 | — | — | WO | disclosed |
| WO-1994010127-A1 | TARTRONIC ACIDS, THEIR ACETALIC ETHERS AND O-ESTERS | DOMPE' FARMACEUTICI S.P.A. (IT) | 1994-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | GPR119 1556/4885MMP13 669/4885KMT2A 1091/4885 |
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | CBLB, CBL, CBLC | GPR119 2464/4885MMP13 4415/4885KMT2A 1486/4885 |
| US-20260138959-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | PDGFRA, KIT, PDGFRB | GPR119 615/4885MMP13 2058/4885KMT2A 983/4885 |
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | GPR119 4128/4885MMP13 2609/4885KMT2A 679/4885 |
| US-20250275952-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | TNNI3, UMPS, TNNT2 | GPR119 3908/4885MMP13 3928/4885KMT2A 1063/4885 |
| US-12559506-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, CLK2 | GPR119 2190/4885MMP13 3772/4885KMT2A 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.